StemCell InstituteTSE:7096 +0.92%69 EBITDA Margin % is 12.05% as of Mar. 2026, which is 37% below its 10-year median of 19.25. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.82 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 939 Biotechnology companies, StemCell Institute ranks better than 77.53% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. StemCell Institute's EBITDA for the
six
months ended in Mar. 2026 was 円168 Mil. StemCell Institute's Revenue for the
six
months ended in Mar. 2026 was 円1,396 Mil. Therefore, StemCell Institute's EBITDA margin for the quarter that ended in Mar. 2026 was 12.05%.
StemCell Institute (TSE:7096) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
StemCell Institute EBITDA Margin % Related Terms
StemCell Institute EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: EBITDA Margin % Comparison
For the Biotechnology subindustry, StemCell Institute's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a EBITDA Margin % of 12.05% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on StemCell Institute and its competitors. This is 37% below median its historical median of 19.25. Over the past decade, StemCell Institute's EBITDA Margin % has ranged from 8.49 to 25.95. According to the industry distribution chart, StemCell Institute ranks #211 out of 939 companies in the Biotechnology industry, placing it in the top 22.5%.
Is StemCell Institute's EBITDA Margin % too high?
StemCell Institute's current EBITDA Margin % of 12.05% is 37% below median its 10-year median of 19.25. Over the past 10 years, this metric has ranged from a low of 8.49 to a high of 25.95. Based on the distribution chart, StemCell Institute ranks #211 out of 939 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's EBITDA Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #211 out of 939 companies for EBITDA Margin %. This places StemCell Institute in the top 23% of its industry — outperforming the majority of peers. Historically, StemCell Institute's own EBITDA Margin % has ranged from 8.49 to 25.95 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on StemCell Institute and its competitors. StemCell Institute's current EBITDA Margin % is 12.05%, which is 37% below median its own 10-year median of 19.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current EBITDA Margin % is 12.05%, which is 37% below median its 10-year median of 19.25. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current EBITDA Margin % is 12.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,813.82.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
EBITDA Margin %: 12.05% (37% below median its 10-year median of 19.25)
GF Value™: 円1,813.82 vs. price of 円768.00 (57.7% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
